Research programme: viral and cancer VLP vaccines - TechnoVax

Drug Profile

Research programme: viral and cancer VLP vaccines - TechnoVax

Alternative Names: Cancer vaccine - TechnoVax; Dengue vaccine - TechnoVax; HIV vaccine - TechnoVax; Inhaled powder influenza VLP vaccine - TechnoVax; Inhaled powder RSV VLP vaccine - TechnoVax; Pandemic influenza vaccine - TechnoVax; Respiratory syncytial virus (RSV) VLP vaccine - TechnoVax; Seasonal tetravalent influenza VLP vaccine - TechnoVax; Universal influenza vaccine - TechnoVax; Virus-like particle (VLP) vaccines - TechnoVax

Latest Information Update: 04 Jun 2014

Price : $50

At a glance

  • Originator TechnoVax
  • Class AIDS vaccines; Cancer vaccines; Dengue vaccines; Influenza A vaccines; Influenza virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Dengue; Influenza virus infections; Parainfluenza virus infections; Respiratory syncytial virus infections
  • Research HIV infections

Most Recent Events

  • 02 Jun 2014 TechnoVax receives a one-year SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAD) for a VLP-based Respiratory Syncytial Virus vaccine development
  • 01 Aug 2013 Preclinical trials in Cancer in USA (Parenteral)
  • 01 Aug 2013 TechnoVax receives SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) for universal influenza vaccine development in Influenza virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top